Compare Alphabet Inc Class A (GOOGL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs TG Therapeutics Inc — how do they compare? Alphabet Inc Class A trades at $371.92 (market cap $4.52T), while TG Therapeutics Inc trades at $54.92 (market cap $8.64B). The key difference: Alphabet Inc Class A is far larger — about 523.1× TG Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GOOGL | TGTX | |
|---|---|---|
Market Cap | $4.52T | $8.64B |
Sector | Media | Health |
52-Week High | $402.62 | $59.06 |
52-Week Low | $182.97 | $26.39 |
Enterprise Value | $4.49T | $8.88B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) stock trades at $370.92, up 3.17% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $350B in 2024 to $402.8B in 2025 and net income surging 32% to $132.2B. Recent quarterly earnings consistently beat expectations, and the company initiated a dividend in 2026. Analyst sentiment remains overwhelmingly positive with 85% buy ratings and a $431.78 consensus price target, suggesting 16% upside potential.
The outlook for GOOGL appears favorable given strong AI-driven growth in cloud and advertising, expanding profitability margins, and solid cash flow generation. Key risks include regulatory scrutiny of antitrust practices, competitive pressures in AI and cloud services, and potential market volatility affecting tech valuations. The stock's current valuation at 28.29x P/E reflects premium pricing for its growth trajectory.
TG Therapeutics (TGTX) trades at $56.20, up 2.39% on the day, with a bullish technical signal and strong analyst consensus (84.6% buy ratings). The stock's momentum is supported by robust revenue growth, with 2025 revenue reaching $616.29M and net income of $447.18M, yielding impressive profitability margins (Gross Margin: 83.05%, ROE: 112.6%). Recent positive clinical updates for Briumvi in multiple sclerosis and schizophrenia trials have fueled investor optimism and media coverage.
The outlook remains positive due to Briumvi's commercial expansion and pipeline progress, though risks include earnings volatility (two recent misses), high valuation multiples (EV/EBITDA: 59.1), and clinical trial dependencies. The current price sits above the consensus price target of $48.50, suggesting near-term valuation concerns may limit upside unless operational execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
